Biotechnology 4 February 2026

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Shares of Hims & Hers Health surged Wednesday, climbing roughly 14% to $24.29 as of 4:48 p.m. ET and reaching as high as $25.45 earlier in the session. The move followed news that the U.S. Food and Drug Administration plans to reconsider restrictions on several peptides—a development that could open a new growth channel for the telehealth firm.

15 April 2026

Biotechnology·NYSE:HIMS·Stock Market

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics yanked its European application for VIOKAT on Tuesday, just a day after striking a $2.9 billion cash deal to be acquired by Neurocrine Biosciences. That move halts a regulatory review Soleno had earlier projected might wrap up by mid-2026.

7 April 2026

Biotechnology·NASDAQ:NBIX·NASDAQ:SLNO·Pharmaceuticals

ImmunityBio (IBRX) stock wobbles in premarket ahead of update call — what traders are watching

ImmunityBio slipped roughly 1.4% in premarket action Tuesday, trading at $10.29. Just a day earlier, the stock finished 6.75% higher at $10.44. Huge moves have marked recent sessions; shares have now soared over 400% year-to-date.

3 March 2026

Biotechnology·NASDAQ:IBRX·Stock Market

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals slipped 2.9% to $8.50 before the bell on Monday, paring recent gains after new clinical data emerged around its hereditary angioedema pipeline.

2 March 2026

Biotechnology·NASDAQ:BCRX

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.

28 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

GRAIL stock dips in premarket after a sharp bounce as Galleri trial fallout hangs over GRAL

GRAIL, Inc slid 5.9% to $54.70 in premarket action Friday, erasing some of Thursday’s 12.2% bounce that pushed shares to $58.10. Investors remain anxious about the Galleri blood test, the company’s key product.

27 February 2026

Biotechnology·Health News·NASDAQ:GRAL·Stock Market

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics AG slipped 1.9% to $60.55 before the bell Friday, pulling back after an 11.85% surge in the previous session that saw the stock finish at $61.74, fueled by renewed takeover rumors.

27 February 2026

Biotechnology·Health News·NASDAQ:CRSP·Stock Market

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares slipped 1.2% to $35.80 in early premarket moves Tuesday, following a 5.7% jump to $36.23 at Monday’s close. Wolfe Research kicked off its coverage with an “Outperform” and tagged a $40 price target. The stock remains below its 52-week peak of $38.69, while roughly 21.6% of the float is sold short, according to MarketBeat.

24 February 2026

Biotechnology·NASDAQ:BIIB·NASDAQ:STOK·Stock Market

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares hovered near $0.42 in premarket trading Tuesday, following a brutal 80% plunge the previous day after its flagship lung-disease therapy fell short in a late-stage trial. With the stock off about $1.71 from its earlier close, traders weighed a harder path to U.S. approval, despite some isolated positives in the data.

24 February 2026

Biotechnology·NASDAQ:GOSS·Pharmaceutical News·Stock Market

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly jumped roughly 4.9% to $1,058.23 late Monday, after Novo Nordisk revealed its next-gen obesity candidate, CagriSema, didn’t measure up to Lilly’s Zepbound in direct comparison. Novo's U.S. shares dropped sharply, sliding 16.4% to $39.63.

23 February 2026

Biotechnology·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL, Inc. shares tumbled 49.8% to $51.00 during Friday afternoon trading, hitting a session low of $45.51 earlier amid heavy volume.

20 February 2026

Biotechnology·NASDAQ:GRAIL·Stock Market

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna jumped roughly 5% to $42.23 in late Friday trading. The vaccine maker managed to beat Wall Street’s revenue expectations and stuck with its 2026 growth targets, despite dealing with an FDA setback on its flu shot.

13 February 2026

Biotechnology·Earnings Reports·NASDAQ:MRNA·Pharmaceuticals·Stock Market

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche Holding is drawing attention as Swiss markets reopen Monday, following word from the drugmaker that its investigational multiple sclerosis therapy, fenebrutinib, met its primary endpoint in a late-stage trial targeting primary progressive multiple sclerosis. Roche closed out Friday at 356.40 Swiss francs, down 0.6%.

8 February 2026

Biotechnology·Healthcare News·Pharmaceuticals·Stock Market·SWX:ROG.S

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly jumped 3.7% to $1,058.18 in late trading Friday after U.S. regulators moved to clamp down on GLP-1 ingredients in unapproved compounded drugs. The Department of Health and Human Services’ general counsel also referred Hims & Hers, a telehealth firm, to the Justice Department for investigation; Hims tumbled almost 12% postmarket.

7 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina tumbled 10.3% to $119.91 on Friday, hitting a low of $117.69, as investors digested the gene-sequencing company’s 2026 forecast released alongside its earnings.

6 February 2026

Biotechnology·China Economy·NASDAQ:ILMN·Stock Market

Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher Scientific Inc picked up around 0.6% to $545.58 by Friday afternoon, clawing back a portion of the nearly 4% drop from the previous session. Over the last 52 weeks, the stock’s been anywhere from $482.42 to $644.27.

6 February 2026

Biotechnology·NYSE:TMO·Stock Market

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

Shares of TransCode Therapeutics Inc jumped nearly 19% Thursday following a U.S. regulatory update related to its lead drug program. The stock traded around $10.23, swinging between $9.08 and $12.30, as volume surged to about 11.5 million shares compared to roughly 8,500 the previous day.

5 February 2026

Biotechnology·OTC:RNAZ.O

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen Inc. shares jumped 8.2% to close at $366.20 Wednesday after investors weighed the company’s quarterly earnings and its guidance for 2026.

5 February 2026

Biotechnology·Earnings Reports·NASDAQ:AMGN·Stock Market

Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus

Shares of Amgen Inc climbed 8.5%, reaching $367.52 in afternoon trading, bucking a decline in the S&P 500 and a wider fall in biotech stocks.

4 February 2026

Biotechnology·Earnings·NASDAQ:AMGN

Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics, the biopharma working on an oral hair-loss treatment, set its IPO price at $17 a share, above the initial range, pulling in roughly $256.3 million. The stock is slated to start trading Wednesday on the New York Stock Exchange under the ticker “MANE.”

4 February 2026

Biotechnology·NYSE:MANE·Pharmaceutical Industry·Stock Market

Biotechnology 4 February 2026 - 15 April 2026